Aclaris Therapeutics (FRA:8AT) Gross-Profit-to-Asset % : 1.20% (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Aclaris Therapeutics Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Aclaris Therapeutics's annualized Gross Profit for the quarter that ended in Mar. 2024 was €2.05 Mil. Aclaris Therapeutics's average Total Assets over the quarter that ended in Mar. 2024 was €170.58 Mil. Therefore, Aclaris Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 1.20%.

Aclaris Therapeutics Gross-Profit-to-Asset % Historical Data

The historical data trend for Aclaris Therapeutics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aclaris Therapeutics Gross-Profit-to-Asset % Chart

Aclaris Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

0.09

1.51

1.29

7.26

5.73

Aclaris Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															1.08	0.47	1.94	21.20	1.20

Competitive Comparison of Aclaris Therapeutics's Gross-Profit-to-Asset %

For the Diagnostics & Research subindustry, Aclaris Therapeutics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aclaris Therapeutics's Gross-Profit-to-Asset % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Aclaris Therapeutics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Aclaris Therapeutics's Gross-Profit-to-Asset % falls into.

Aclaris Therapeutics Gross-Profit-to-Asset % Calculation

Aclaris Therapeutics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	12.075	/	( (240.339	+	181.02)	/ 2 )
	=	12.075	/	210.6795
	=	5.73 %

Aclaris Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	2.052	/	( (181.02	+	160.14)	/ 2 )
	=	2.052	/	170.58
	=	1.20 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Aclaris Therapeutics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Aclaris Therapeutics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Aclaris Therapeutics (FRA:8AT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aclaris Therapeutics Inc (FRA:8AT) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

ACRS:USA

Address

640 Lee Road, Suite 200, Wayne, PA, USA, 19087

Website

https://www.aclaristx.com

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

Aclaris Therapeutics (FRA:8AT) Headlines

No Headlines